# Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.

> **NCT05142709** · — · COMPLETED · sponsor: **Fudan University** · enrollment: 1197 (actual)

## Conditions studied

- Metastatic Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Anti-PD-1 Immune Checkpoint Inhibitors

## Key facts

- **NCT ID:** NCT05142709
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-31
- **Primary completion:** 2023-09-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 1197 (ACTUAL)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05142709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05142709, "Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05142709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*